Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a single shot before surgery shield your heart?

NCT ID NCT06324461

Prevention Sponsor: The University of Hong Kong Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a single injection of a GLP-1 drug (dulaglutide), given 1 to 14 days before planned non-cardiac surgery, can reduce heart muscle injury in 372 adults at risk. Participants are randomly assigned to receive the drug or standard care. The goal is to see if this simple preventive step lowers heart damage and related complications after surgery.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 372 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2024

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years * Planned elective intermediate to high risk non-cardiac surgery * Anticipated to remain hospitalized for at least one night after surgery * Voluntarily agrees to participate by providing written informed consent Exclusion Criteria: * History of symptomatic hypoglycemia within 1 month of recruitment * History of pancreatitis * Diabetic retinopathy * Personal or family history of medullary thyroid carcinoma (MTC) * Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) * Acute coronary syndrome, decompensated heart failure, cardiogenic shock, or myocarditis within 1 month of recruitment * Stroke or transient ischemic attack within 1 month of recruitment * Known severe liver disease (Child-Pugh B or C) * Stage 5 chronic kidney disease (estimated glomerular filtration rate (eGFR) by Modified Diet in Renal Disease (MDRD) equation \< 15 mL/min) * Recent use of GLP-1 RA within 1 month of recruitment * Known allergy or hypersensitivity to GLP-1 RA * Women of childbearing age who are not taking effective contraception, or who are pregnant or breast-feeding * Use of Dipeptidyl peptidase-4 inhibitor(DPP4i)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Myocardial injury are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Myocardial injury

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Duchess of Kent Children's Hospital at Sandy Bay

    NOT_YET_RECRUITING

    Hong Kong, Hong Kong SAR, China

  • Queen Mary Hospital

    RECRUITING

    Hong Kong, Hong Kong SAR, China

  • Tung Wah Hospital

    RECRUITING

    Hong Kong, Hong Kong SAR, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.